This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, R. Articles by Arihiro, K. Search for Related Content PubMed PubMed Citation Articles by Kim, R. Articles by Arihiro, K. Related Collections Cancer Immunology Cancer Immunology: Adaptive Immunity

Tumor-Driven Evolution of Immunosuppressive Networks during Malignant Progression

¹ International Radiation Information Center; ² Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University; and ³ Department of Pathology, Hiroshima University Hospital, Hiroshima, Japan

Requests for reprints: Ryungsa Kim, International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi Minami-ku, Hiroshima 734-8553, Japan. Phone/Fax: 81-82-257-5877; E-mail: rkim{at}hiroshima-u.ac.jp.

Tumors evolve mechanisms to escape immune control by a process called immune editing, which provides a selective pressure in the tumor microenvironment that could lead to malignant progression. A variety of tumor-derived factors contribute to the emergence of complex local and regional immunosuppressive networks, including vascular endothelial growth factor, interleukin-10, transforming growth factor-ß, prostaglandin E₂, and soluble phosphatidylserine, soluble Fas, soluble Fas ligand, and soluble MHC class I–related chain A proteins. Although deposited at the primary tumor site, these secreted factors could extend immunosuppressive effects into the local lymph nodes and the spleen, promoting invasion and metastasis. Vascular endothelial growth factors play a key role in recruiting immature myeloid cells from the bone marrow to enrich the microenvironment as tumor-associated immature dendritic cells and tumor-associated macrophages. The understanding of the immunosuppressive networks that evolve is incomplete, but several features are emerging. Accumulation of tumor-associated immature dendritic cells may cause roving dendritic cells and T cells to become suppressed by the activation of indoleamine 2,3-dioxygenase and arginase I by tumor-derived growth factors. Soluble phosphatidylserines support tumor-associated macrophages by stimulating the release of anti-inflammatory mediators that block antitumor immune responses. Soluble Fas, soluble FasL, and soluble MHC class I–related chain A proteins may help tumor cells escape cytolysis by cytotoxic T cells and natural killer cells, possibly by counterattacking immune cells and causing their death. In summary, tumor-derived factors drive the evolution of an immunosuppressive network which ultimately extends immune evasion from the primary tumor site to peripheral sites in patients with cancer. (Cancer Res 2006; 66(11): 5527-36)

This article has been cited by other articles:

				A. Wallace, V. Kapoor, J. Sun, P. Mrass, W. Weninger, D. F. Heitjan, C. June, L. R. Kaiser, L. E. Ling, and S. M. Albelda Transforming Growth Factor-{beta} Receptor Blockade Augments the Effectiveness of Adoptive T-Cell Therapy of Established Solid Cancers Clin. Cancer Res., June 15, 2008; 14(12): 3966 - 3974. [Abstract] [Full Text] [PDF]

				Y.-C. Chang, T.-C. Chen, C.-T. Lee, C.-Y. Yang, H.-W. Wang, C.-C. Wang, and S.-L. Hsieh Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3 Blood, May 15, 2008; 111(10): 5054 - 5063. [Abstract] [Full Text] [PDF]

				A. Jorritsma, A. D. Bins, T. N.M. Schumacher, and J. B.A.G. Haanen Skewing the T-Cell Repertoire by Combined DNA Vaccination, Host Conditioning, and Adoptive Transfer Cancer Res., April 1, 2008; 68(7): 2455 - 2462. [Abstract] [Full Text] [PDF]

				A. Ricciardi, A. R. Elia, P. Cappello, M. Puppo, C. Vanni, P. Fardin, A. Eva, D. Munroe, X. Wu, M. Giovarelli, et al. Transcriptome of Hypoxic Immature Dendritic Cells: Modulation of Chemokine/Receptor Expression Mol. Cancer Res., February 1, 2008; 6(2): 175 - 185. [Abstract] [Full Text] [PDF]

				R.-I. You, Y.-C. Chang, P.-M. Chen, W.-S. Wang, T.-L. Hsu, C.-Y. Yang, C.-T. Lee, and S.-L. Hsieh Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3) Blood, February 1, 2008; 111(3): 1480 - 1488. [Abstract] [Full Text] [PDF]

				J. M. Chemnitz, D. Eggle, J. Driesen, S. Classen, J. L. Riley, S. Debey-Pascher, M. Beyer, A. Popov, T. Zander, and J. L. Schultze RNA fingerprints provide direct evidence for the inhibitory role of TGF{beta} and PD-1 on CD4+ T cells in Hodgkin lymphoma Blood, November 1, 2007; 110(9): 3226 - 3233. [Abstract] [Full Text] [PDF]

				A. Weigert, N. Tzieply, A. von Knethen, A. M. Johann, H. Schmidt, G. Geisslinger, and B. Brune Tumor Cell Apoptosis Polarizes Macrophages Role of Sphingosine-1-Phosphate Mol. Biol. Cell, October 1, 2007; 18(10): 3810 - 3819. [Abstract] [Full Text] [PDF]

				W. J. Pickford, A. J.M. Watson, and R. N. Barker Different Forms of Helper Tolerance to Carcinoembryonic Antigen: Ignorance and Regulation Clin. Cancer Res., August 1, 2007; 13(15): 4528 - 4537. [Abstract] [Full Text] [PDF]

				A. Wallace, D. F. LaRosa, V. Kapoor, J. Sun, G. Cheng, A. Jassar, A. Blouin, L.-M. Ching, and S. M. Albelda The Vascular Disrupting Agent, DMXAA, Directly Activates Dendritic Cells through a MyD88-Independent Mechanism and Generates Antitumor Cytotoxic T Lymphocytes Cancer Res., July 15, 2007; 67(14): 7011 - 7019. [Abstract] [Full Text] [PDF]

				T. Raskovalova, A. Lokshin, X. Huang, Y. Su, M. Mandic, H. M. Zarour, E. K. Jackson, and E. Gorelik Inhibition of Cytokine Production and Cytotoxic Activity of Human Antimelanoma Specific CD8+ and CD4+ T Lymphocytes by Adenosine-Protein Kinase A Type I Signaling Cancer Res., June 15, 2007; 67(12): 5949 - 5956. [Abstract] [Full Text] [PDF]

				I. L. Tourkova, G. V. Shurin, S. Wei, and M. R. Shurin Small Rho GTPases Mediate Tumor-Induced Inhibition of Endocytic Activity of Dendritic Cells J. Immunol., June 15, 2007; 178(12): 7787 - 7793. [Abstract] [Full Text] [PDF]

				H. Koehler, D. Kofler, A. Hombach, and H. Abken CD28 Costimulation Overcomes Transforming Growth Factor-{beta}-Mediated Repression of Proliferation of Redirected Human CD4+ and CD8+ T Cells in an Antitumor Cell Attack Cancer Res., March 1, 2007; 67(5): 2265 - 2273. [Abstract] [Full Text] [PDF]

				G. Zhou and H. I. Levitsky Natural Regulatory T Cells and De Novo-Induced Regulatory T Cells Contribute Independently to Tumor-Specific Tolerance J. Immunol., February 15, 2007; 178(4): 2155 - 2162. [Abstract] [Full Text] [PDF]